Pluristem Therapeutics Inc. [PSTI] Stock trading around $1.83 per share: What’s Next?


Pluristem Therapeutics Inc. [NASDAQ: PSTI] stock went on an upward path that rose over 24.49% on Monday, amounting to a one-week price increase of more than 21.19%. The company report on January 10, 2022 that Biotechnology Company Pluristem, and Israel’s Largest Food Producer Tnuva, Launch Landmark Collaboration to Establish Cultured Food Platform.

Collaboration uniquely combines Pluristem’s technological expertise in mass-scale, cost-effective, consistent cell production with Tnuva’s power multipliers in consumer-packaged goods, research and development (R&D), consumer branding marketing, and sales and distribution with the goal to accelerate time to market.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


Tnuva Group is Israel’s largest food conglomerate, founded 96 years ago, with over $2 billion dollars in annual revenues.

Over the last 12 months, PSTI stock dropped by -78.45%. The one-year Pluristem Therapeutics Inc. stock forecast points to a potential upside of 76.78. The average equity rating for PSTI stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $56.77 million, with 32.00 million shares outstanding and 28.24 million shares in the current float. Compared to the average trading volume of 224.40K shares, PSTI stock reached a trading volume of 55613784 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Pluristem Therapeutics Inc. [PSTI]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for PSTI shares is $7.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on PSTI stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Alliance Global Partners have made an estimate for Pluristem Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 04, 2021. The new note on the price target was released on December 10, 2020, representing the official price target for Pluristem Therapeutics Inc. stock. Previously, the target price had yet another raise to $12, while Jefferies analysts kept a Buy rating on PSTI stock.

The Average True Range (ATR) for Pluristem Therapeutics Inc. is set at 0.15 The Price to Book ratio for the last quarter was 1.20, with the Price to Cash per share for the same quarter was set at 1.96.

PSTI Stock Performance Analysis:

Pluristem Therapeutics Inc. [PSTI] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 21.19. With this latest performance, PSTI shares dropped by -19.03% in over the last four-week period, additionally sinking by -50.00% over the last 6 months – not to mention a drop of -78.45% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PSTI stock in for the last two-week period is set at 48.07, with the RSI for the last a single of trading hit 57.77, and the three-weeks RSI is set at 43.69 for Pluristem Therapeutics Inc. [PSTI]. The present Moving Average for the last 50 days of trading for this stock 2.2948, while it was recorded at 1.5340 for the last single week of trading, and 3.2338 for the last 200 days.

Insight into Pluristem Therapeutics Inc. Fundamentals:

Pluristem Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.10 and a Current Ratio set at 6.10.

>> 7 Top Picks for the Post-Pandemic Economy <<

Pluristem Therapeutics Inc. [PSTI] Insider Position Details

There are presently around $6 million, or 14.10% of PSTI stock, in the hands of institutional investors. The top three institutional holders of PSTI stocks are: ARK INVESTMENT MANAGEMENT LLC with ownership of 925,361, which is approximately -31.501% of the company’s market cap and around 0.10% of the total institutional ownership; NIA IMPACT ADVISORS, LLC, holding 732,135 shares of the stock with an approximate value of $1.08 million in PSTI stocks shares; and RENAISSANCE TECHNOLOGIES LLC, currently with $0.57 million in PSTI stock with ownership of nearly -4.552% of the company’s market capitalization.

Positions in Pluristem Therapeutics Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 23 institutional holders increased their position in Pluristem Therapeutics Inc. [NASDAQ:PSTI] by around 764,611 shares. Additionally, 23 investors decreased positions by around 841,196 shares, while 16 investors held positions by with 2,790,598 shares. The mentioned changes placed institutional holdings at 4,396,405 shares, according to the latest SEC report filing. PSTI stock had 3 new institutional investments in for a total of 68,523 shares, while 7 institutional investors sold positions of 171,692 shares during the same period.